Note 8 - Subsequent Events	6 Months Ended
Jun. 30, 2026
Notes to Financial Statements
Subsequent Events [Text Block]	Note 8 - Subsequent Events The Company has evaluated subsequent events through the filing of this Quarterly Report on Form 10-Q and determined that there have been no recognized subsequent events that have occurred that would require adjustments to the Company’s disclosures in the condensed consolidated financial statements. The following are nonrecognized subsequent events through the filing of this Quarterly Report on Form 10-Q. 2026 Reverse Stock Split On July 16, 2026, Genprex completed the 2026 Reverse Split of its issued and outstanding shares of common stock at a ratio of 1-for-22. The 2026 Reverse Split did not change the number of authorized shares of common stock or par value. All references in these financial statements to shares, share prices, exercise prices, and other applicable share and per share information in all periods have been adjusted, on a retroactive basis, to reflect the 2026 Reverse Split (See “Note 4 – Equity – 2026 Reverse Stock Split”). No fractional shares were issued in connection with the 2026 Reverse Split, but in lieu thereof, stockholders who would otherwise be entitled to a fractional share of common stock were automatically entitled to receive an additional fraction of a share of common stock so as to round up to the next whole share. Except as otherwise stated, the outstanding share numbers and related data as reported in this Quarterly Report on Form 10-Q, including in the condensed consolidated financial statements and these Notes thereto, is stated as of June 30, 2026; subsequent to June 30, 2026, as a result of completion of the above-described adjustments arising from the Company’s rounding up of fractional shares in the 2026 Reverse Split, the Company issued an aggregate of 72,263 shares in connection with rounding up of 2026 Reverse Split fractional shares. Such issuances are not included in the outstanding share data reported herein as of June 30, 2026, but are included in the Company’s outstanding shares as of August 10, 2026 as reported on the cover page of this Quarterly Report on Form 10-Q. Share Issuances On July 1, 2026, Genprex issued 228 shares of its common stock to the Chairman of its Scientific Advisory Board in consideration for services. On July 17, 2026, Genprex issued an aggregate of 72,263 shares in connection with rounding up of 2026 Reverse Split fractional shares associated with beneficial owners of the Company’s common stock. At-The-Market Offering From July 1, 2026 through the date of filing of this Quarterly Report on Form 10-Q, Genprex has sold 241,000 shares of its common stock for aggregate net proceeds to the Company totaling approximately $1.53 million under the 2023 ATM Facility.

Note 8 - Subsequent Events

6 Months Ended

Jun. 30, 2026

Note 8 - Subsequent Events

The Company has evaluated subsequent events through the filing of this Quarterly Report on Form 10-Q and determined that there have been no recognized subsequent events that have occurred that would require adjustments to the Company’s disclosures in the condensed consolidated financial statements. The following are nonrecognized subsequent events through the filing of this Quarterly Report on Form 10-Q.

2026 Reverse Stock Split

On July 16, 2026, Genprex completed the 2026 Reverse Split of its issued and outstanding shares of common stock at a ratio of 1-for-22. The 2026 Reverse Split did not change the number of authorized shares of common stock or par value. All references in these financial statements to shares, share prices, exercise prices, and other applicable share and per share information in all periods have been adjusted, on a retroactive basis, to reflect the 2026 Reverse Split (See “Note 4 – Equity – 2026 Reverse Stock Split”). No fractional shares were issued in connection with the 2026 Reverse Split, but in lieu thereof, stockholders who would otherwise be entitled to a fractional share of common stock were automatically entitled to receive an additional fraction of a share of common stock so as to round up to the next whole share. Except as otherwise stated, the outstanding share numbers and related data as reported in this Quarterly Report on Form 10-Q, including in the condensed consolidated financial statements and these Notes thereto, is stated as of June 30, 2026; subsequent to June 30, 2026, as a result of completion of the above-described adjustments arising from the Company’s rounding up of fractional shares in the 2026 Reverse Split, the Company issued an aggregate of 72,263 shares in connection with rounding up of 2026 Reverse Split fractional shares. Such issuances are not included in the outstanding share data reported herein as of June 30, 2026, but are included in the Company’s outstanding shares as of August 10, 2026 as reported on the cover page of this Quarterly Report on Form 10-Q.

Share Issuances

On July 1, 2026, Genprex issued 228 shares of its common stock to the Chairman of its Scientific Advisory Board in consideration for services. On July 17, 2026, Genprex issued an aggregate of 72,263 shares in connection with rounding up of 2026 Reverse Split fractional shares associated with beneficial owners of the Company’s common stock.

At-The-Market Offering

From July 1, 2026 through the date of filing of this Quarterly Report on Form 10-Q, Genprex has sold 241,000 shares of its common stock for aggregate net proceeds to the Company totaling approximately $1.53 million under the 2023 ATM Facility.